Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes

An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome

(2016) Peter P. Wibroe et al.   JOURNAL OF CONTROLLED RELEASE

Surprising lack of liposome-induced complement activation by artificial 1,3-diamidophospholipids in vitro

(2016) Simon Bugna et al.   Nanomedicine-Nanotechnology Biology and Medicine

Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro

(2016) Tamás Mészáros et al.   Nanomedicine-Nanotechnology Biology and Medicine

Complement Propriety and Conspiracy in Nanomedicine: Perspective and a Hypothesis

(2016) Seyed Moein Moghimi   Nucleic Acid Therapeutics

Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals

(2014) Janos Szebeni   MOLECULAR IMMUNOLOGY

Single-Walled Carbon Nanotube Surface Control of Complement Recognition and Activation

(2013) Alina J. Andersen et al.   ACS Nano

Delivering Nanoparticles to Lungs while Avoiding Liver and Spleen through Adsorption on Red Blood Cells

(2013) Aaron C. Anselmo et al.   ACS Nano

An international serum standard for application in assays to detect human complement activation products

(2013) Grethe Bergseth et al.   MOLECULAR IMMUNOLOGY

Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium

(2013) P. Kolhar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles

(2013) P. L. Rodriguez et al.   SCIENCE

Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward

(2012) S. Moein Moghimi et al.   ADVANCED DRUG DELIVERY REVIEWS

A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines

(2012) János Szebeni et al.   ADVANCED DRUG DELIVERY REVIEWS

Pulmonary intravascular macrophages and lung health: What are we missing?

(2012) David Schneberger et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

PRINT: A Novel Platform Toward Shape and Size Specific Nanoparticle Theranostics

(2011) Jillian L. Perry et al.   ACCOUNTS OF CHEMICAL RESEARCH

Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective

(2011) S.M. Moghimi et al.   Annual Review of Pharmacology and Toxicology

Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine

(2011) You-Qiang Wu et al.   JOURNAL OF IMMUNOLOGY

Inhibiting the C5–C5a receptor axis

(2011) Trent M. Woodruff et al.   MOLECULAR IMMUNOLOGY

Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome

(2011) János Szebeni et al.   Nanomedicine-Nanotechnology Biology and Medicine

Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphere−Serum Interface: Implications for Stealth Nanoparticle Engineering

(2010) Islam Hamad et al.   ACS Nano

Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: The challenges ahead

(2010) S.M. Moghimi et al.   JOURNAL OF CONTROLLED RELEASE

Effect of particle shape on phagocytosis of CdTe quantum dot–cystine composites

(2010) Zhisong Lu et al.   MedChemComm

Size and shape effects in the biodistribution of intravascularly injected particles

(2009) P. Decuzzi et al.   JOURNAL OF CONTROLLED RELEASE

In Human Macrophages the Complement Component C5a Induces the Expression of Oncostatin M via AP-1 Activation

(2008) Stefan P. Kastl et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY